U.S., Nov. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07920081) titled 'Psilocybin for Amblyopia - Targeting Critical Periods in Humans' on Oct. 30.
Brief Summary: The purpose of this study is to evaluate whether ingestion of a drug called psilocybin can increase the effectiveness of amblyopia therapy in adults with amblyopia. Psilocybin is a naturally-occurring psychoactive compound found in many species of mushrooms. It can be ingested orally and can result in strong but short-term (4-6 hours) effects such as changes in perception, thoughts, and emotions.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Amblyopia
Intervention:
BEHAVIORAL: Amblyopia Therapy
May include: eye-patc...